Oncolys BioPharma Inc
Oncolys BioPharma Inc. is dedicated to advancing medical science through innovative treatments for cancer and infectious diseases, leveraging virology-based drug discovery technologies. The company focuses on developing novel drugs and diagnostics, with a mission to contribute to a healthier world by providing impactful therapeutic options and establishing stable revenue streams from pharmaceutical and diagnostic businesses.
Industries
Nr. of Employees
small (1-50)
Oncolys BioPharma Inc
343 Thornall Street, Suite 505, Edison, NJ 08837
Patents
Products
Oncolytic adenovirus immunotherapy (telomerase-promoter selective)
A conditionally replicating adenoviral therapeutic engineered to preferentially replicate in tumor cells via telomerase-promoter regulation, developed for loco-regional and systemic oncology indications and combination regimens with radiation and immune checkpoint inhibitors.
Reporter-expressing recombinant viral diagnostic reagent
A recombinant viral reagent that expresses a reporter protein for detection and imaging of tumor or inflammatory cells in assay systems.
Antiviral nucleoside analog (reverse transcriptase inhibitor)
A nucleoside analog antiviral developed for treatment of viral infections (including HIV) with worldwide exclusive license arrangements.
Novel small-molecule anti-cancer compound (depsipeptide class)
Discovery-stage novel depsipeptide small molecule series developed for oncology indications and available for licensing under exclusive agreements.
Oncolytic adenovirus immunotherapy (telomerase-promoter selective)
A conditionally replicating adenoviral therapeutic engineered to preferentially replicate in tumor cells via telomerase-promoter regulation, developed for loco-regional and systemic oncology indications and combination regimens with radiation and immune checkpoint inhibitors.
Reporter-expressing recombinant viral diagnostic reagent
A recombinant viral reagent that expresses a reporter protein for detection and imaging of tumor or inflammatory cells in assay systems.
Antiviral nucleoside analog (reverse transcriptase inhibitor)
A nucleoside analog antiviral developed for treatment of viral infections (including HIV) with worldwide exclusive license arrangements.
Novel small-molecule anti-cancer compound (depsipeptide class)
Discovery-stage novel depsipeptide small molecule series developed for oncology indications and available for licensing under exclusive agreements.
Services
In-licensing and out-licensing of drug candidates and technologies, and formation of strategic alliances with academic and industry partners for development and commercialization.
Project planning and operational management of preclinical studies and clinical trials while outsourcing manufacturing and other execution activities to external providers.
Development and technology transfer of virus-based diagnostic assay systems and licensing of assay technology to clinical testing organizations and medical institutions.
Management and coordination of manufacturing service agreements with contract manufacturers for clinical and preclinical material production.
In-licensing and out-licensing of drug candidates and technologies, and formation of strategic alliances with academic and industry partners for development and commercialization.
Project planning and operational management of preclinical studies and clinical trials while outsourcing manufacturing and other execution activities to external providers.
Development and technology transfer of virus-based diagnostic assay systems and licensing of assay technology to clinical testing organizations and medical institutions.
Management and coordination of manufacturing service agreements with contract manufacturers for clinical and preclinical material production.
Expertise Areas
- Virology-based drug discovery
- Oncolytic virus therapy development
- Viral-vector diagnostic development
- Clinical trial management (Phase I-II)
Key Technologies
- Oncolytic adenoviral vectors
- Genetically engineered reporter viruses for tumor detection
- Telomerase-promoter-driven expression constructs
- Nucleoside reverse transcriptase inhibitor chemistry
News & Updates
Announcement regarding the change of executive officers.
Announcement about the disposal of treasury stock as restricted stock compensation.
Notice of the adoption of OBP-601 (censavudine) for Phase 2/3 HEALEY ALS Platform Trial.
Update on the President's column.
Progress on the comprehensive evaluation consultation for tumor lysis virus OBP-301.
Announcement regarding the change of executive officers.
Announcement about the disposal of treasury stock as restricted stock compensation.
Notice of the adoption of OBP-601 (censavudine) for Phase 2/3 HEALEY ALS Platform Trial.
Update on the President's column.
Progress on the comprehensive evaluation consultation for tumor lysis virus OBP-301.